Maximum Somatic Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden Predicts the Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

Maximum Somatic Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden Predicts the Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

Introduction: Recent studies exhibited the unstable prediction ability of blood-based tumor mutational burden (bTMB) when predicting the response of immune checkpoint inhibitors (ICIs) therapy in patients with non-small cell lung cancer (NSCLC). Circulating tumor DNA (ctDNA) abundance, usually repre...

Full description

Bibliographic Details
Main Authors: Yiting Dong, Yixiang Zhu, Minglei Zhuo, Xiaomin Chen, Yinpeng Xie, Jianchun Duan, Hua Bai, Shiguang Hao, Zicheng Yu, Yuting Yi, Yanfang Guan, Jie Yuan, Xuefeng Xia, Xin Yi, Jie Wang, Zhijie Wang
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Cancers
Subjects:
non-small-cell lung cancer
NSCLC
maximum somatic allele frequency
MSAF
tumor mutation burden
TMB
Online Access:https://www.mdpi.com/2072-6694/14/22/5649

Internet

https://www.mdpi.com/2072-6694/14/22/5649

Similar Items